MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Intellia Therapeutics Inc

Fechado

SetorSaúde

7.33 11.06

Visão Geral

Variação de preço das ações

24h

Atual

Mín

6.53

Máximo

7.58

Indicadores-chave

By Trading Economics

Rendimento

6.8M

-129M

Vendas

3.8M

13M

EPS

-1.27

Margem de lucro

-1,001.227

Funcionários

403

EBITDA

8.3M

-134M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+441.44% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-335M

838M

Abertura anterior

-3.73

Fecho anterior

7.33

Sentimento de Notícias

By Acuity

26%

74%

73 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Intellia Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de set. de 2024, 17:01 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 de set. de 2024, 11:00 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Intellia Therapeutics Inc Previsão

Preço-alvo

By TipRanks

441.44% parte superior

Previsão para 12 meses

Média 36.06 USD  441.44%

Máximo 74 USD

Mínimo 9 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Intellia Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

20 ratings

15

Comprar

4

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 9.3Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

73 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.